Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
06 Novembre 2023 - 2:00PM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage
biotechnology company and leader in the discovery and development
of novel therapeutics for the treatment of fibrotic diseases,
presented three posters highlighting PLN-101095, a novel inhibitor
of integrins αvβ8 and αvβ1. These posters were presented as part of
the 38th Annual Meeting of the Society for Immunotherapy of Cancer
(SITC) held November 1 - 5, 2023.
Trial in Progress: Phase 1a Trial of PLN-101095, an
Integrin αvβ8 and αvβ1 Inhibitor, as Monotherapy and in Combination
with Pembrolizumab, in Treatment-resistant Patients with Advanced
or Metastatic Solid Tumors
Pliant is conducting a first-in-human, open-label,
dose-escalation study designed to evaluate the safety,
tolerability, and pharmacokinetics of PLN-101095 as monotherapy and
in combination with pembrolizumab in adult patients with advanced
or metastatic solid tumors and documented disease progression after
at least 3 months from the start of treatment with pembrolizumab,
and with no other available effective treatment options.
Integrin αvβ1 is Expressed in Multiple Solid Tumor Types
and Drives the Adhesion of Cancer Associated Fibroblast to Latent
TGF-β
Expression of αvβ1 protein was evaluated across a diverse set of
human tumor tissues and cancer-associated fibroblasts (CAF) to
investigate its functional role in cancer biology. PLN-101095, a
selective small molecule inhibitor of αvβ8 and αvβ1 integrins, was
evaluated in combination with anti-mPD-1 on fibrotic markers in the
EMT6 tumor model. PLN-101095 was shown to block the binding of
cancer-associated fibroblasts (CAF) to the TGF-β latency-associated
peptide (LAP) in a dose-dependent manner. EMT6 tumor tissues
treated with PLN-101095 and anti-mPD-1 showed a significant
reduction in fibrotic markers compared to anti-αvβ8 and anti-mPD-1.
PLN-101095 was also shown to effectively reduce the expression of
the fibroblast activation marker αSMA in ex vivo-treated human
breast tumor tissues.
Selective Targeting of Integrins αVβ8 and αVβ1 within
the Dynamic Ecosystem of Pancreatic Cancer to Improve the Overall
Anti-tumor Response
PLN-101095, a selective small molecule inhibitor of αvβ8 and
αvβ1 integrins, was assessed in preclinical models of pancreatic
ductal adenocarcinoma (PDA). PLN-101095 was shown to decrease
primary tumor growth, improve chemosensitivity in metastatic PDA
with gene expression changes associated with favorable immune
response and improved prognosis. Results showed that selective
targeting of αvβ8 and αvβ1 with PLN-101095 or αvβ1 signaling with
PLN-76104 potently inhibited primary tumor growth, spread and
improve chemotherapy response in models of PDA.
These posters are available on the Publications page of the
Pliant’s website at https://pliantrx.com/publications/.
About Pliant Therapeutics, Inc.Pliant
Therapeutics is a clinical-stage biopharmaceutical company and
leader in the discovery and development of novel therapeutics for
the treatment of fibrotic diseases. Pliant's lead product
candidate, bexotegrast (PLN-74809), is an oral, small molecule,
dual selective inhibitor of αvß6 and αvß1 integrins that is in
development in the lead indications for the treatment of idiopathic
pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or
PSC. Bexotegrast has received Fast Track Designation and Orphan
Drug Designation from the U.S. Food and Drug Administration (FDA)
in IPF and PSC and Orphan Drug Designation from the European
Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, a
Phase 2b trial of bexotegrast in IPF. Pliant has also developed
PLN-1474, a small molecule, selective inhibitor of αvß1 integrin
for the treatment of nonalcoholic steatohepatitis, or NASH with
liver fibrosis. Pliant has initiated a Phase 1 study for its third
clinical program, PLN-101095, a small molecule, dual-selective
inhibitor of αvß8 and αvß1 integrins, that is being developed for
the treatment of solid tumors. In addition to clinical-stage
programs, Pliant currently has a preclinical program targeting
muscular dystrophies. For additional information, please
visit: www.PliantRx.com. Follow us on social
media X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," and similar expressions (as well as other
words or expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking statements.
These statements include those regarding the results of our studies
of our development candidates and their potential for further
development. Because such statements deal with future events and
are based on our current expectations, they are subject to various
risks and uncertainties and actual results, performance or
achievements of Pliant Therapeutics could differ materially from
those described in or implied by the statements in this press
release. These forward-looking statements are subject to risks and
uncertainties, including those related to the development and
commercialization of our product candidates, including any delays
in our ongoing or planned preclinical or clinical trials, the
impact of current macroeconomic and marketplace conditions, our
reliance on third parties for critical aspects of our development
operations, the risks inherent in the drug development process, the
risks regarding the accuracy of our estimates of expenses and
timing of development, our capital requirements and the need for
additional financing, including the availability of additional term
loans under our loan facility, and our ability to obtain and
maintain intellectual property protection for our product
candidates. These and additional risks are discussed in the
sections titled "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in our
Quarterly Report on Form 10-Q for the period ended June 30, 2023
which is available on the SEC's website at www.sec.gov. Unless
otherwise noted, Pliant is providing this information as of the
date of this news release and does not undertake any obligation to
update any forward-looking statements contained in this document as
a result of new information, future events or otherwise.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and
Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Grafico Azioni Pliant Therapeutics (NASDAQ:PLRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Pliant Therapeutics (NASDAQ:PLRX)
Storico
Da Mag 2023 a Mag 2024